Clinical Trial

SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-07.
Trial Details
NCT Number NCT06873659
Lead Sponsor Qurgen Inc.
Conditions Solid Tumor, Gastric Cancer, Liver Cancer
Enrollment 96 participants
Start Date 2025-02-26
Primary Completion 2027-04 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-03